Published in Br J Clin Pharmacol on June 01, 1988
Effects of tobacco and non-tobacco cigarette smoking on endothelium and platelets. Clin Pharmacol Ther (1985) 1.26
A simple and safe technique for sterile autologous platelet labelling using "Monovette" vials. Eur J Nucl Med (1984) 1.00
Lack of effect of aspirin on cigarette smoke-induced increase in circulating endothelial cells. Haemostasis (1987) 0.94
Endothelial injury by nicotine and its prevention. Experientia (1978) 0.93
Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo. Postgrad Med J (1987) 0.86
Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction. Eur Heart J (1996) 1.54
Platelet lipoxygenase defect (Wien-Penzing defect) in two patients with myocardial infarction. Am J Hematol (1991) 1.43
Visualization of intestinal splenosis by somatostatin receptor scintigraphy. Am J Gastroenterol (1998) 1.43
Extremely-low-dose aspirin (1 mg per day) renders human platelets more sensitive to antiaggregation prostaglandins. N Engl J Med (1984) 1.05
Physiology of upward transport in the human female genital tract. Ann N Y Acad Sci (2007) 1.00
Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol (2000) 0.98
Diagnostic value of onset-recordings and marker annotations in dual chamber pacemaker stored electrograms. Europace (2003) 0.95
Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers. Thromb Res (2000) 0.93
Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. J Exp Med (1996) 0.91
Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer (1999) 0.91
Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med (2001) 0.91
Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer (2001) 0.90
Autologous low-density lipoprotein labelling allows characterization of human atherosclerotic lesions in vivo as to presence of foam cells and endothelial coverage. Eur J Nucl Med (1991) 0.90
Imaging of human atherosclerotic lesions using 123I-low-density lipoprotein. Eur J Nucl Med (1986) 0.89
H.D.L. cholesterol in peripheral vascular disease. Lancet (1979) 0.89
Neuroendocrine differentiation in head and neck squamous cell carcinoma. J Laryngol Otol (2012) 0.89
Epoprostenol and platelet deposition in atherosclerosis. Lancet (1984) 0.88
Evaluation of esophageal tracheal combitube in cardiopulmonary resuscitation. Crit Care Med (1987) 0.88
Sensitivity of platelets to prostaglandins in cornary heart disease and angina pectoris. Prostaglandins (1981) 0.88
Ventilation with the esophageal tracheal combitube in cardiopulmonary resuscitation. Promptness and effectiveness. Chest (1988) 0.86
Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo. Postgrad Med J (1987) 0.86
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology (1999) 0.84
Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med (1998) 0.84
123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br J Cancer (1998) 0.84
Treatment of hypercholesterolaemia in children. Lancet (1992) 0.83
Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. Br J Clin Pharmacol (1982) 0.83
Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood (2001) 0.83
Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol (2000) 0.83
Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging (2010) 0.83
Isoprostane 8-epi-prostaglandin F2 alpha is a potent contractor of human peripheral lymphatics. Lymphology (1997) 0.83
Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract. Anticancer Res (2001) 0.82
Decreased stability of prostacyclin after acute myocardial infarction. Lancet (1987) 0.82
Regulation of human lymph contractility by prostaglandins and thromboxane. Lymphology (1984) 0.82
111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med (2001) 0.82
Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells. Life Sci (1996) 0.81
Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. J Allergy Clin Immunol (1996) 0.81
Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type. Br J Cancer (2001) 0.81
Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med (1998) 0.81
Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type. J Natl Cancer Inst (1999) 0.81
18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver. Liver (2000) 0.81
Effect of leukotrienes C4 and D4 on prostaglandin I2-liberation from human lymphatics. Lymphology (1986) 0.80
Eicosanoid production and lymphatic responsiveness in human cigarette smokers compared with non-smokers. Lymphology (2000) 0.80
Effect of epoprostenol on platelet deposition on synthetic artery grafts. Lancet (1984) 0.80
Antimitotic actions of vasodilatory prostaglandins--clinical aspects. Agents Actions Suppl (1997) 0.80
[Beta-blockader, pindolol, in the therapy of angina pectoris; a report on a multicentric controlled study]. Wien Med Wochenschr (1979) 0.79
Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease. Lancet (1990) 0.79
Platelet function and prostaglandins in patients with peripheral vascular disease treated with calcium dobesilate. Prostaglandins Leukot Med (1987) 0.79
The prostacyclin synthesis stimulating plasma factor is unchanged during acute angina pectoris. Prostaglandins Leukot Med (1985) 0.79
Enhanced prostacyclin formation in veins of women under chronical treatment with oral contraceptive drugs. Pharmacol Res Commun (1980) 0.79
Beneficial effect of long-term PGE1-treatment in left ventricular heart failure. Prostaglandins Leukot Essent Fatty Acids (1989) 0.79
Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. Blood (1994) 0.79
Prostacyclin synthesis stimulating plasma factor in patients with peripheral vascular disease. Prostaglandins Leukot Med (1987) 0.79
Vascular prostacyclin, platelet sensitivity to prostaglandins and platelet-specific proteins in diabetes mellitus. Analysis of type of diabetes, state of metabolic control and diabetic microangiopathy. Horm Metab Res Suppl (1981) 0.79
Low density lipoprotein receptors: preliminary results on "in vivo" study. Wien Klin Wochenschr (1991) 0.79
Diagnosis and therapy of neuroendocrine tumours. Q J Nucl Med Mol Imaging (2010) 0.78
13,14-Dihydro-prostaglandin E1 decreases low-density lipoprotein influx into rabbit aorta. Eur J Pharmacol (1992) 0.78
An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy: usefulness of hepatobiliary imaging for differential diagnosis. Am J Gastroenterol (2000) 0.78
Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression. Scand J Gastroenterol (2002) 0.78
[Defects in the prostaglandin system. V. Inherited (?) disorder of prostacyclin degradation in the plasma (Wien-Döbling defect)]. Wien Klin Wochenschr (1985) 0.78
Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem (1997) 0.78
Beneficial effect of prostaglandin I2 on smooth muscle cell proliferation. Prog Clin Biol Res (1987) 0.78
20 mg aspirin daily--evidence for a clinical future of this extremely low-dose in arterial disease? Vasa (1988) 0.78
Uterine mechanisms of ipsilateral directed spermatozoa transport: Evidence for a contribution of the utero-ovarian countercurrent system. Eur J Obstet Gynecol Reprod Biol (2009) 0.78
[Defects in the prostaglandin system. II. Familial platelet-prostacyclin receptor defect (Wien-Hietzing defect)--pathogenetic significance for (early) development of atherosclerosis?]. Wien Klin Wochenschr (1985) 0.78
99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging (2005) 0.78
Modified LDL decreases the binding of prostaglandin E2, I2, and E1 onto monocytes in patients with peripheral vascular disease. Arterioscler Thromb Vasc Biol (1997) 0.77
Studies on the dehydrogenation of proline and hydroxyproline in animal tissue. Enzymologia (1970) 0.77
Enhanced prostaglandin I2-formation of human lymphatics during pulsatile perfusion. Lymphology (1986) 0.77
Ticlopidine and platelet function in healthy volunteers. Thromb Res (1992) 0.77
Effects of bopindolol on platelet function in hypertension at rest and during exercise. Prostaglandins Leukot Essent Fatty Acids (1990) 0.77
Prostacyclin (PGI2) contracts normal and varicose human saphenous veins. Vasa (1984) 0.77
Platelet response during prostaglandin E1-therapy in patients with non-insulin-dependent diabetes mellitus. Thromb Res (1997) 0.77
Levels of eicosanoids (6-oxo-PGF1 alpha and 8-epi-PGF2 alpha) in human and porcine lymphatics and lymph. Lymphology (1998) 0.77
Clinical value of platelet migration test in patients with peripheral vascular disease. Vasa (1983) 0.77
A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease. Prostaglandins (1990) 0.77
Comparison of four rapid D-Dimer tests for diagnosis of pulmonary embolism. Thromb Res (1996) 0.77
Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease. Am J Hematol (1985) 0.77
[Do passive smokers have an increased risk of thrombosis?]. Wien Klin Wochenschr (1989) 0.77
Hypertension and beneficial treatment with beta-blocking agents does not change the platelet sensitivity to the antiaggregatory prostaglandins. Prostaglandins Leukot Med (1982) 0.77
Value of platelet sensitivity to antiaggregatory prostaglandins (PGI2, PGE1, PGD2) in 50 patients with myocardial infarction at young age. Prostaglandins Med (1981) 0.77
Survival rate and causes of death in patients with pacemakers: dependence on symptoms leading to pacemaker implantation. Eur Heart J (1988) 0.77
Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations. Br J Cancer (1993) 0.76
Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma. J Nucl Med (1998) 0.76
Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease. Thromb Res (1992) 0.76
Pathomechanisms of atherosclerosis beneficially affected by prostaglandin E1 (PGE1)--an update. Vasa Suppl (1989) 0.76
Comparison of iodine-123 low-density lipoprotein (LDL) and indium-111 LDL binding to mononuclear cells of healthy normolipaemic controls and patients with heterozygous familial hypercholesterolaemia. Eur J Nucl Med (1994) 0.76
Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease. Prog Clin Biol Res (1989) 0.76